Press Releases


Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19

October 28, 2020

Tags |  Product

- Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials   - Patients will have no out-of-pocket costs for the medication INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S.




Lilly Reports Third-Quarter Financial Results, Updates Guidance

October 27, 2020

Tags |  Financial

- Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent.   - Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance,




New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

October 23, 2020

Tags |  Product

- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes   -




Lilly Declares Fourth-Quarter 2020 Dividend

October 19, 2020

Tags |  Financial

INDIANAPOLIS , Oct. 19, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December 10, 2020 , to shareholders of record at the close of




Lilly Announces Agreement to Acquire Disarm Therapeutics

October 15, 2020

Tags |  Corporate

Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced a definitive




Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial

October 12, 2020

Tags |  Product

‒ Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease   ‒ These Phase 2 data reinforce the continued evaluation of mirikizumab in the ongoing, pivotal VIVID Phase 3




Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment

October 9, 2020

Tags |  Product

- Largest Real-World Study of Patient-Reported Outcomes in People with Migraine Shows the Use of Novel CGRP Monoclonal Antibody Class May Improve Migraine INDIANAPOLIS , Oct. 9, 2020 /PRNewswire/ -- Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for




Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement

October 8, 2020

Tags |  Financial

INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial




Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen

October 8, 2020

Tags |  Product

Further results from NIAID-sponsored ACTT-2 Trial Presented Today INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical




Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity

October 8, 2020

Local coalition launches pledge and website, calling on more Central Indiana organizations to sign on, make commitments and track progress publicly INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- A local coalition of corporate and civic organizations has launched the Indy Racial Equity Pledge to hold